Calcineurin inhibitors in liver transplantation: To be or not to be

Transplantation Proceedings

Volumn 43, Issue 6, 2011, Pages 2220-2223

  Castroagudin J F ^a   Molina, E ^a   Varo, E ^a  

^a University Hospital of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BASILIXIMAB; CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; VASCULOTROPIN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ARTICLE; BONE MARROW TOXICITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHOLANGITIS; CHRONIC KIDNEY FAILURE; CLINICAL EFFECTIVENESS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DNA REPAIR; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERLIPIDEMIA; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; MONOTHERAPY; MOUTH ULCER; MULTICENTER STUDY (TOPIC); NEOPLASM; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT CANCER; RECURRENT DISEASE; REINFECTION; SIDE EFFECT; SURVIVAL; UNSPECIFIED SIDE EFFECT; WOUND HEALING IMPAIRMENT;

CALCINEURIN; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; PATIENT SELECTION; RISK ASSESSMENT; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 80051700466     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.05.012     Document Type: Article

References (28)

1. E. Varo-Pérez, and J.F. Castroagudín The future of liver transplantation Transplant Proc 42 2010 613
2. E. Varo, A. López, and J.F. Castroagudín Alternative immunosuppression for acute renal failure in liver transplantation: role of ultra-low tacrolimus and basiliximab Transplant Proc 34 2002 1567
3. E. Varo, A. López, and C. Rivero Initial immunosuppression in liver transplant recipients with impaired renal function Transplant Proc 37 2005 3909
4. J.M. Neuberger, R.D. Mamelok, and P. Neuhaus Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the "ReSpECT" study Am J Transplant 9 2009 327
5. T.A. Gonwa, M.L. Mai, and L.B. Melton End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 72 2001 1934
6. A. Pawarode, D.M. Fine, and P.J. Thuluwath Independent risk factors and natural history of renal dysfunction in liver transplant recipients Liver Transpl 9 2003 741
7. A.O. Ojo, P.J. Held, and F.K. Port Chronic renal failure after transplantation of a nonrenal organ New Engl J Med 349 2003 931
8. A.S. Paramesh, S. Roayaie, and Y. Doan Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease Clin Transplant 18 2004 94
9. G.P. Pageaux, L. Rostaing, and Y. Calmus Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation Liver Transpl 12 2006 1755
10. C. Pontón, L. Vizcaíno, and S. Tomé Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction Transplant Proc 42 2010 656
11. T.G. Heffron, G.A. Smallwood, and L. Davis Sirolimus-based immunosuppressive protocol for calcineurin sparing in liver transplantation Transplant Proc 34 2002 1522
12. S. Nair, J. Eason, and G. Loss Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients Liver Transpl 9 2003 126
13. G.W. Neff, M. Montalbano, and G. Slapak-Green Sirolimus therapy in ortothopic liver transplant recipients with calcineurin inhibitor related chronic renal insufficiency Transplant Proc 35 2003 3029
14. K.D. Fairbanks, J.A. Eustace, and D. Fine Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus Liver Transpl 9 2003 1079
15. E.Q. Sanchez, A.P. Martin, and T. Ikegami Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years Transplant Proc 37 2005 4416
16. P. De Simone, P. Carrai, and A. Precisi Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function Transpl Int 22 2009 278
17. J.F. Castroagudín, E. Molina, and R. Romero Improvement of renal function after switching from calcineurin inhibitor to Everolimus in liver transplant recipients with chronic renal dysfunction Liver Transpl 15 2009 1792
18. M. Guba, C. Graeb, and K.W. Jauch Pro- and anticancer effects of immnunosupressive agents used in liver transplantation Transplantation 77 2004 1777
19. J.M. Campistol, J. Eris, and R. Oberbauer Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation J Am Soc Nephrol 17 2006 581
20. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
21. N.M. Kneteman, J. Oberholzer, and M. Al Saghier Sirolimus- immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma Liver Transpl 10 2004 1301
22. M.A. Zimmerman, J.F. Trotter, and M. Wachs Sirolimus-based immunosupression following liver transplantation for hepatocellular carcinoma Liver Transpl 14 2008 633
23. J. Zhou, Z. Wang, and Q. Wu Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria Transplant Proc 40 2008 3548
24. M. Vivarelli, A. Dazzi, and M. Zanello Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma Transplantation 89 2010 227
25. C. Toso, S. Merani, and D.L. Bigam Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma Hepatology 51 2010 1237
26. A. Nocera, E. Andorno, and A. Tagliamacco Sirolimus therapy in liver transplant patients: an initial experience at a single center Transplant Proc 40 2008 1950
27. J.F. Castroagudín, E. Molina, and S. Tomé Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence Transplant Proc 41 2009 1003
28. C. Toso, G.A. Meeberg, and D.L. Bigam De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects Transplantation 83 2007 1162